TALPHERA INC (TLPH)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$1.200.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · TLPH
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 0.0 | — | 0.7 | 0.0 | 0.4 | 5.4 | 2.3 | 2.2 | 8.0 | 17.4 | 19.3 | 5.2 | 29.5 | — | — |
| Total Revenues | — | — | — | — | — | — | — | — | 2.2 | 8.0 | 17.4 | 19.3 | 5.2 | 29.5 | — | — |
| Cost of Revenues | — | — | — | — | 0.0 | 0.6 | 6.0 | 6.8 | 4.0 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 8.0 | 7.5 | 8.5 | 12.0 | 17.0 | 15.5 | 36.3 | 45.0 | — | — | — | — | — | — | — | — |
| R&D Expenses | 6.7 | 6.0 | 6.7 | 5.5 | 3.3 | 2.4 | 4.0 | 4.7 | 13.1 | 19.4 | 21.4 | 22.5 | 24.5 | 26.3 | 24.9 | 13.6 |
| Operating Income | (14.7) | (13.5) | (15.3) | (16.9) | (25.3) | (18.1) | (41.0) | (54.2) | (35.7) | (38.7) | (32.0) | (20.0) | (37.6) | (6.7) | (29.7) | (19.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | 0.1 | 1.1 | 2.2 | 3.3 | 2.5 | 2.2 | 3.3 | 2.8 | 3.0 | 2.6 | 1.5 | 2.3 | 2.3 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.1 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.3 |
| Other Non-Operating Income / Expenses | (0.3) | (0.9) | 2.2 | 6.6 | 84.4 | 1.0 | 0.6 | 1.0 | (11.4) | (13.5) | (11.2) | (3.7) | 4.3 | (16.8) | (1.4) | 1.6 |
| EBT, Incl. Unusual Items | — | — | — | (10.3) | 59.1 | (17.1) | (40.4) | (53.2) | (47.1) | (52.2) | (43.2) | (23.6) | (37.6) | (6.7) | (29.7) | (19.4) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.7) | (0.0) | 0.8 | 0.0 | 0.0 | — | — |
| Net Income | ||||||||||||||||
| Net Income | (15.1) | (14.3) | (13.0) | (18.4) | 47.8 | (35.1) | (40.4) | (53.2) | (47.1) | (51.5) | (43.2) | (24.4) | (33.4) | (23.4) | (33.4) | (20.1) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.20) | (0.34) | (0.50) | (1.29) | 5.73 | (5.86) | — | — | — | (1.10) | (0.95) | (0.55) | (0.77) | — | — | — |
| Diluted EPS | — | — | — | (1.29) | 5.72 | (5.86) | — | — | — | (1.10) | (0.95) | (0.60) | (0.91) | — | — | — |
| Basic Weighted Avg Shares | 75.5 | 42.4 | 25.8 | 14.3 | 7.4 | 6.0 | — | — | — | 46.9 | 45.3 | 44.3 | 43.4 | — | — | — |
| Diluted Weighted Avg Shares | — | — | — | 14.3 | 7.4 | 6.0 | — | — | — | 46.9 | 45.3 | 44.5 | 44.3 | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | (16.6) | (23.7) | (16.1) | (39.1) | (52.5) | (35.2) | (36.9) | (29.9) | (18.0) | (36.8) | (6.1) | (29.1) | (18.8) |
| EBIT | (14.7) | (13.5) | (15.3) | (16.9) | (25.3) | (18.1) | (41.0) | (54.2) | (35.7) | (38.7) | (32.0) | (20.0) | (37.6) | (6.7) | (29.7) | (19.4) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | -0.0% | -0.0% | -0.0% | -0.0% | 1.3% | 0.1% | -3.2% | 0.0% | 0.0% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.